86 related articles for article (PubMed ID: 25335934)
1. PPAR-γ promotes endothelial cell migration by inducing the expression of Sema3g.
Liu W; Li J; Liu M; Zhang H; Wang N
J Cell Biochem; 2015 Apr; 116(4):514-23. PubMed ID: 25335934
[TBL] [Abstract][Full Text] [Related]
2. SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.
Mirza SL; Upton PD; Hodgson J; Gräf S; Morrell NW; Dunmore BJ
Vascul Pharmacol; 2024 Jun; 155():107381. PubMed ID: 38795838
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
4. Effects of SEMA3G on migration and invasion of glioma cells.
Zhou X; Ma L; Li J; Gu J; Shi Q; Yu R
Oncol Rep; 2012 Jul; 28(1):269-75. PubMed ID: 22562223
[TBL] [Abstract][Full Text] [Related]
5. The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-γ in the regulation of macrophage inflammatory protein-3α at early onset of diabetes.
Qi W; Holian J; Tan CY; Kelly DJ; Chen XM; Pollock CA
Int J Biochem Cell Biol; 2011 Mar; 43(3):383-92. PubMed ID: 21109018
[TBL] [Abstract][Full Text] [Related]
6. Sema3G activates YAP and promotes VSMCs proliferation and migration via Nrp2/PlexinA1.
Luo XY; Fu X; Liu F; Luo JY; Chen AF
Cell Signal; 2023 May; 105():110613. PubMed ID: 36720439
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin-dependent vascular remodeling.
Chen DY; Sun NH; Chen X; Gong JJ; Yuan ST; Hu ZZ; Lu NN; Körbelin J; Fukunaga K; Liu QH; Lu YM; Han F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586674
[TBL] [Abstract][Full Text] [Related]
8. Klotho is a target gene of PPAR-gamma.
Zhang H; Li Y; Fan Y; Wu J; Zhao B; Guan Y; Chien S; Wang N
Kidney Int; 2008 Sep; 74(6):732-9. PubMed ID: 18547997
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing.
Westerweel PE; den Ouden K; Nguyen TQ; Goldschmeding R; Joles JA; Verhaar MC
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F379-84. PubMed ID: 18077601
[TBL] [Abstract][Full Text] [Related]
10. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells.
Min Q; Bai YT; Jia G; Wu J; Xiang JZ
Exp Mol Pathol; 2010 Feb; 88(1):133-7. PubMed ID: 19796634
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects.
Calabrò P; Samudio I; Safe SH; Willerson JT; Yeh ET
J Vasc Res; 2005; 42(6):509-16. PubMed ID: 16155367
[TBL] [Abstract][Full Text] [Related]
12. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
Desouza CV; Gerety M; Hamel FG
Vascul Pharmacol; 2009; 51(2-3):162-8. PubMed ID: 19520186
[TBL] [Abstract][Full Text] [Related]
13. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ.
Zhang Y; Yang X; Bian F; Wu P; Xing S; Xu G; Li W; Chi J; Ouyang C; Zheng T; Wu D; Zhang Y; Li Y; Jin S
J Mol Cell Cardiol; 2014 Jul; 72():85-94. PubMed ID: 24594319
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone antagonizes vascular endothelial growth factor signaling and nuclear factor of activated T cells activation in cardiac valve endothelium.
Sander TL; Noll L; Klinkner DB; Weihrauch D; He BJ; Kaul S; Zangwill SD; Tweddell JS; Pritchard KA; Oldham KT
Endothelium; 2006; 13(3):181-90. PubMed ID: 16840174
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a novel member of murine semaphorin family.
Taniguchi M; Masuda T; Fukaya M; Kataoka H; Mishina M; Yaginuma H; Watanabe M; Shimizu T
Genes Cells; 2005 Aug; 10(8):785-92. PubMed ID: 16098142
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic response of advanced glycation end products (AGEs) involves PPARgamma.
Devi MS; Sudhakaran PR
Indian J Biochem Biophys; 2012 Feb; 49(1):18-24. PubMed ID: 22435140
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
18. Damage to vascular endothelial cells by high insulin levels is associated with increased expression of ChemR23, and attenuated by PPAR-gamma agonist, rosiglitazone.
Hao F; Mu JW; Zhang HJ; Kuang HY; Yu QX; Bai MM; Meng P
Neuro Endocrinol Lett; 2015; 36(1):59-66. PubMed ID: 25789586
[TBL] [Abstract][Full Text] [Related]
19. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
20. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.
Aljada A; O'Connor L; Fu YY; Mousa SA
Angiogenesis; 2008; 11(4):361-7. PubMed ID: 18810647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
